C the Signs Raises $8M to Expand AI-Powered Cancer Prediction Platform to the U.S.
C the Signs is revolutionizing cancer detection with an AI-driven approach that integrates seamlessly into existing healthcare workflows, providing clinicians with personalized, data-driven insights to improve early diagnosis and save lives.
Company Name: C the Signs
Location: London, UK
Industry: AI for Cancer Detection & Healthcare
Funding Details
- Amount: $8M
- Investor: Khosla Ventures (Lead)
Purpose of Investment
- Expand operations from the UK to the U.S.
- Enhance AI-powered early cancer detection technology.
Leadership
- CEO & Co-Founder: Dr. Bea Bakshi
Product
C the Signs has developed an AI-based cancer prediction system designed to identify at-risk patients at the earliest and most curable stage of the disease.
Key Features
- Explainable AI Model: Analyzes electronic health record (EHR) data beyond basic risk factors (e.g., age, gender) to assess personalized cancer risk.
- Targeted Screening: Flags high-risk individuals for early testing while ruling out those who do not need screening, reducing unnecessary testing.
- Clinical Impact: Already deployed across the UK’s National Health Service (NHS), helping detect cancers earlier and improve patient outcomes.
About the Company
C the Signs is revolutionizing cancer detection with an AI-driven approach that integrates seamlessly into existing healthcare workflows, providing clinicians with personalized, data-driven insights to improve early diagnosis and save lives.
Future Plans
With this funding, C the Signs will accelerate its expansion into the U.S. healthcare market, bringing its AI-powered cancer risk assessment platform to more healthcare providers, insurers, and hospital systems worldwide.
